Skip to content

Trial · Interventional

SuspendedEarly phase 1Registry data

The Effect of Oxytocin on Face Perception

NCTNCT02091817 (opens ClinicalTrials.gov in a new tab)Other idsor010712ctilOther idISF, 384/10
Open at ClinicalTrials.govAsk about this trial

This trial is suspended.

Reason given at the registry: We are currently engaged in other behavioral study.

Overview

Status
Suspended
Phase
Early phase 1
Enrollment
100 participants (estimated)
Sponsor
Soroka University Medical Center · Other
Design
Randomized · Double masking
Countries
1 country

Israel

Start
Nov 2013
Primary completion
Dec 2016 (estimated)
Completion
Dec 2017 (estimated)
First posted
19 Mar 2014 (estimated)
Last update posted
2 Jul 2015 (estimated)
Conditions
Healthy · Congenital Prosopagnosia

Timeline

1 trial · 1 stopped early

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201320142015201620172018
  1. Ph Early 1

    The Effect of Oxytocin on Face Perception

    NCT02091817

    Nov 2013 to est. Dec 2017

    Suspended

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The purpose of this study is to determine whether oxytocin affect face perception

Interventions

  • OxytocinDrug
  • PlaceboDrug

Arms2

  • Other

    Control group

    Control group will be administered oxytocin and placebo, in a double-blind randomized order.

  • Experimental

    congenital prosopagnosia

    Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Memory performance

    Time frame · Day 2 (24 hours after encoding)

    Registry description

    At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are %accuracy and %dwell time of eye movements towards each region in the faces the participants saw.

Secondary outcomes(1)

  1. Mood measurement

    Time frame · Day 1 (after oxytocin/placebo uptake)

    Registry description

    Participants will fill a PANAS mood questionnaire in order to monitor the effects of mood and fatigue of oxytocin/placebo. We will use ANOVA on the total score of the test in order to verify that differences in performance are not due to change in mood or fatigue after substance uptake.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Systematic review · 2011

3 results

A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research.

MacDonald et al. 2011Psychoneuroendocrinologycited by 276

PMID 21429671DOI 10.1016/j.psyneuen.2011.02.015PUB-21429671

Full text at the publisher3 results
Publisher pageSee results (3)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 80 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * normal or corrected to normal vision Exclusion Criteria: * minors * pregnancy (according to a pregnancy test taken by subjects prior to participation) * a history of asthma or nasal polyps * cardiac disorders * hyponatremia * acute or chronic renal insufficiency * liver cirrhosis * neurological disease * other chronic disease * dementia, or lack of judgment

PepBank is a research reference. Talk to a doctor before you use any peptide.